Ameriprise’s ELITE PHARMACEUTICAL ELI Stock Holding History

Ameriprise’s Portfolio ELI Stock Details ELI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-75,000	Closed	-$15K	–	4178
2015 Q2	$15K	Hold	75,000	–	–	﹤0.01%	3994
2015 Q1	$18K	Hold	75,000	–	–	﹤0.01%	3766
2014 Q4	$17K	Buy	+75,000	New	+$17K	﹤0.01%	3667

Other funds holding ELI

Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

JAFL

Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return

GIA

Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return

PCA

Personal Capital Advisors Redwood City, California $20.6B AUM 13.65% 1-Year Est. Return

WRM

Westport Resources Management Westport, Connecticut $138M AUM 14.6% 1-Year Est. Return

Ameriprise's ELI Position: Q3 2015 in Review

Ameriprise sold out of ELITE PHARMACEUTICAL (ELI) in Q3 2015, closing a stake of 75,000 shares — an estimated $15K sold.

Ameriprise first reported a position in ELI in Q4 2014 and held it in 3 quarters. The position peaked at $18K in Q1 2015. 5 funds tracked by Wall St. Rank hold ELI as of Q3 2015.

Ameriprise reported no remaining ELITE PHARMACEUTICAL position as of Q3 2015 after selling out during the quarter.
Ameriprise sold 75,000 ELITE PHARMACEUTICAL shares in Q3 2015, an estimated $15K.
Ameriprise first reported a position in ELITE PHARMACEUTICAL in Q4 2014 and held it in 3 quarters.
Ameriprise's ELITE PHARMACEUTICAL position peaked at $18K in Q1 2015.
5 funds tracked by Wall St. Rank held ELITE PHARMACEUTICAL as of Q3 2015.

Based on Ameriprise's 13F filing for Q3 2015, filed 12 Nov 2015.